Announced
Synopsis
The Carlyle Group, an American multinational company with operations in private equity, alternative asset management and financial services, agreed to invest in Orifarm Group, one of the largest European suppliers of parallel imported and generic pharmaceuticals. Financial terms were not disclosed. "This strategic investment will significantly enhance our ability to capitalise on the attractive opportunities, both organic and inorganic, that we positioned Orifarm for following the transformational asset deal with Takeda in 2020. We are confident that this marks the start of an exciting future for the business, our employees, and other stakeholders," Erik Sandberg, Orifarm Group CEO.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Sort
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.